Practice patterns among penile cancer surgeons performing dynamic sentinel lymph node biopsy and radical inguinal lymph node dissection in men with penile cancer: A eUROGEN survey
Authors
Fankhauser, Christian DAyres, B. E.
Issa, Allaudin
Albersen, M.
Watkin, N.
Muneer, A.
Sangar, Vijay K
Parnham, Arie S
Affiliation
Department of Urology, The Christie NHS Foundation Trusts, ManchesterIssue Date
2021
Metadata
Show full item recordAbstract
Dynamic sentinel lymph node biopsy (DSNB) and radical inguinal lymph node dissection (ILND) are important in the management of penile cancer patients, but high-level evidence for preoperative, perioperative, and postoperative management remains scarce. According to an online survey of 35 surgeons from ten European countries, 57% perform >10 ILND procedures per year and 86% offer DSNB. Furthermore, management differs substantially for dye injection site, use of lymphoscintigraphy, preferred incision sites, techniques for lymphatic control, duration of empiric antibiotic therapy, perioperative thromboprophylaxis, time points for drain removal, and definition of the ILND dissection floor. Consensus was observed for the use of perioperative antibiotics (although not duration and type) and the borders for ILND template definitions. We conclude that there is significant variation in patient management among eUROGEN penile cancer surgeons. This heterogeneity may confound multicentre studies; therefore, a consensus to standardise inguinal node management in penile cancer across European penile cancer centres is warranted. Patient summary: Our survey reveals that preferences and surgical techniques for inguinal lymph node sampling and removal varies significantly between European penile cancer surgeons. Consensus is needed to standardise the management approach for penile cancer.Citation
Fankhauser CD, Ayres BE, Issa A, Albersen M, Watkin N, Muneer A, et al. Practice Patterns Among Penile Cancer Surgeons Performing Dynamic Sentinel Lymph Node Biopsy and Radical Inguinal Lymph Node Dissection in Men with Penile Cancer: A eUROGEN Survey. European Urology Open Science. 2021 Feb;24:39–42.Journal
European Urology Open ScienceDOI
10.1016/j.euros.2020.12.009PubMed ID
34337494Additional Links
https://dx.doi.org/10.1016/j.euros.2020.12.009Type
OtherLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.euros.2020.12.009